Opticann Inc. was founded by pioneers in the medical cannabis space who come from the healthcare and pharmaceutical industries. Established by former MedReleaf and Cynapsus Therapeutics executives, Opticann’s pharmaceutical-focused team has 40 years’ combined experience in the pharmaceutical industry and over 20 years of experience in clinical medicine and medical cannabis product development.
We produce and market world-class medical cannabis products in Canada, the U.S. directly and through strategic partners in Australia and New Zealand.
Evidence Based Cannabinoids
Opticann believes the therapeutic and medical potential of the multitude of active cannabinoids (over 100 identified by researchers) and terpenes in cannabis can effectively help millions of people with multiple disease conditions. This revolution in medical treatment with cannabinoids started with THC and CBD and is expanding rapidly as research and understanding of other cannabinoids in the cannabis and hemp plants increases.
Many medical patients and their healthcare practitioners are still developing their understanding of the therapeutic potential of cannabinoids for improving peoples’ lives. Our goal is to help accelerate this education and provide the most effective products based on scientific evidence and innovative technology.
Trusted Pharmaceutical Technology
Opticann’s CB4™ brand of medical cannabinoid products are based on trusted pharmaceutical technology platforms that are proven to enhance performance of products—for rapid and maximum effect, while minimizing unwanted effects.
Our CBD product formats may be familiar to most medical patients: oral capsules, sublingual strips, and topically administered products in the form of creams and gels. All Opticann products are based on innovative pharmaceutical technology that deliver results consistently, safely, and in convenient dosage forms. These dosage forms are clinically tested and optimized to deliver active ingredients for effective results.
Our Promise to All Patients: